Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirapazamine - Teclison

Next Previous
Drug Profile

Tirapazamine - Teclison

Alternative Names: NSC 130181; RG-001 - Teclison; SR 259075; SR 4233; TATE; TEC-001; Tirazone; WIN 59075

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SRI International; Stanford Cancer Institute
  • Developer Merck Sharp & Dohme Corp.; SRI International; Teclison; Zhejiang Raygene Pharmaceuticals
  • Class Antineoplastics; Radiation-sensitising agents; Reducing agents; Small molecules; Triazines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Colorectal cancer; Liver cancer; Non-small cell lung cancer
  • Discontinued Glioma; Head and neck cancer; Malignant melanoma

Most Recent Events

  • 21 Mar 2025 Zhejiang Raygene Pharmaceuticals terminates a phase-I/II trial in Liver cancer in China (Intra-arterial), due to strategic shift in company operations (NCT06848556)
  • 25 Feb 2025 Zhejiang Raygene Pharmaceuticals plans a phase II/III trial in liver cancer in April 2025 (NCT06844357)
  • 09 Jan 2025 Jiangsu Alphamab Biopharmaceuticals in collaboration with Zhejiang Raygene Pharmaceuticals terminates phase IIa trial in Colorectal cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (Parenteral), due to business operation strategy adjustment (NCT06834399)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top